| Autor: |
Costantini M; GSK , Siena, Italy., Callegaro A; GSK , Rixensart, Belgium., Beran J; Vaccination and Travel Medicine Centre , Hradec Králové, Czechia.; Department for Tropical, Travel Medicine and Immunization, Institute for Postgraduate Medical Education in Prague , Prague 10, Czechia., Berlaimont V; GSK , Wavre, Belgium., Galgani I; GSK , Siena, Italy. |
| Jazyk: |
angličtina |
| Zdroj: |
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2020 Sep 01; Vol. 16 (9), pp. 2274-2279. Date of Electronic Publication: 2020 Jan 17. |
| DOI: |
10.1080/21645515.2019.1700712 |
| Abstrakt: |
In tick-borne encephalitis (TBE)-endemic regions, long-term vaccination programs are efficient in preventing the disease. A booster dose of a polygeline-free inactivated TBE vaccine ( Encepur Adults , GSK), administered approximately 3 years post-primary vaccination according to 1 of 3 licensed vaccination schedules in adults and adolescents, resulted in antibody persistence for 10 years post-boosting. We used different power-law models (PLMs) to predict long-term persistence of anti-TBE virus neutralization test (NT) antibody titers over a period of 20 years post-booster dose, based on individual antibody NT titers measured for 10 years post-booster vaccination. The PLMs were fitted on pooled data for all vaccine schedules. A mean NT titer of 261 (95% prediction interval: 22-3096), considerably above the accepted threshold of protection (NT titers ≥10), was predicted 20 years post-booster vaccination with TBE vaccine. Our modeled data suggest that the intervals of booster doses could be increased without compromising protection against TBE. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
